Aimmune Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing treatments to protect children with food allergies from accidental exposure. Aimmune Therapeutics serves customers in the United States.
Aimmune pushes the boundaries of medicine to help reduce the burden of serious and potentially life-threatening food, gastrointestinal (GI), and metabolic-related diseases — enabling people to live life on their own terms.
Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.
[caption id="attachment_11499" align="aligncenter" width="334"] Aimmune Therapeutics, Inc[/caption]
Product Approval Dates
31‐JAN‐2020 Peanut (Arachis hypogaea) Allergen Powder
We’re on a mission to transform the lives of patients and their families by developing pharmaceutical therapies to prevent, manage, and treat food, GI, and metabolic-related diseases.
Aimmune uses multiple modalities to treat a broad range of food, GI, and metabolic-related diseases, including biologics and immunotherapy for the treatment of allergic conditions, and is dedicated to advancing science and technology platforms for every challenge.
